DaVita HealthCare Partners Inc. (NYSE:DVA) – Analysts at William Blair dropped their FY2017 EPS estimates for DaVita HealthCare Partners in a research report issued to clients and investors on Monday. William Blair analyst M. Kaczor now forecasts that the company will post earnings per share of $3.42 for the year, down from their prior estimate of $3.51. William Blair also issued estimates for DaVita HealthCare Partners’ Q4 2017 earnings at $0.89 EPS, Q1 2018 earnings at $0.80 EPS, Q2 2018 earnings at $0.94 EPS, Q3 2018 earnings at $0.95 EPS, Q4 2018 earnings at $0.90 EPS and FY2018 earnings at $3.60 EPS.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The business had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. During the same quarter last year, the company posted $0.95 earnings per share. The company’s revenue was up 5.2% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “DaVita HealthCare Partners Inc. Expected to Earn FY2017 Earnings of $3.42 Per Share (DVA)” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/14/davita-healthcare-partners-inc-expected-to-earn-fy2017-earnings-of-3-42-per-share-dva.html.

Other research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. SunTrust Banks, Inc. set a $57.00 target price on shares of DaVita HealthCare Partners and gave the company a “hold” rating in a report on Sunday, October 15th. Royal Bank Of Canada lowered their target price on shares of DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. KeyCorp reiterated a “hold” rating on shares of DaVita HealthCare Partners in a report on Monday. Finally, Wolfe Research upgraded shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $63.00.

DaVita HealthCare Partners (NYSE DVA) opened at $54.99 on Tuesday. The stock has a market cap of $10,407.74, a price-to-earnings ratio of 15.71, a P/E/G ratio of 11.05 and a beta of 0.98. DaVita HealthCare Partners has a 12 month low of $52.51 and a 12 month high of $70.16. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40.

DaVita HealthCare Partners declared that its Board of Directors has authorized a share repurchase program on Tuesday, October 10th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

A number of hedge funds and other institutional investors have recently bought and sold shares of DVA. Thrivent Financial For Lutherans increased its holdings in DaVita HealthCare Partners by 4.4% during the first quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock worth $389,000 after buying an additional 240 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in DaVita HealthCare Partners by 491.6% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 25,274 shares of the company’s stock worth $1,637,000 after purchasing an additional 21,002 shares during the period. Eqis Capital Management Inc. boosted its position in DaVita HealthCare Partners by 2.2% during the second quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock worth $298,000 after purchasing an additional 100 shares during the period. Founders Capital Management LLC boosted its position in DaVita HealthCare Partners by 0.6% during the second quarter. Founders Capital Management LLC now owns 93,824 shares of the company’s stock worth $6,076,000 after purchasing an additional 520 shares during the period. Finally, PGGM Investments bought a new position in DaVita HealthCare Partners during the second quarter worth about $28,598,000. Institutional investors and hedge funds own 84.73% of the company’s stock.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History and Estimates for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.